XM does not provide services to residents of the United States of America.
A
A

Amgen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change American Electric Power Company Inc AEP.OQ +2.1% Walgreens Boots Alliance Inc WBA.OQ +1.8% Autodesk Inc ADSK.OQ +1.8% Xcel Energy Inc XEL.OQ +1.6% Amgen Inc AMGN.OQ +1.6% Bottom Performers Percent Change Netflix Inc NFLX.OQ -8.1% Advanced Micro Devices Inc AMD.OQ -4.0% Micron Technology Inc MU.OQ -3.9% NVIDIA Corp NVDA.OQ -3.7% CrowdStrike Holdings Inc CRWD.OQ -3.3% The Nasdaq 100
A
A
M
N
N
W
X
A
U
C

Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing

BRIEF-Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing April 17 (Reuters) - Amgen Inc AMGN.O : AMGEN INC SAYS CEO ROBERT A. BRADWAY'S 2023 TOTAL COMPENSATION WAS $22.6 MILLION VERSUS $21.4 MILLION IN 2022 – SEC FILING Source text for Eikon: [ID: https://bitly.ws/3idLq ] Furt
A

U.S. 3M, J&J, Nuvalent

U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent April 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including 3M, J&J and Nuvalent, on Wednesday. HIGHLIGHTS * 3M Co MMM.N : JP Morgan cuts target price to $110 from $118 * J&J JNJ.N : RBC cuts target price to $175 from $181 * Nuvalent Inc NUVL.O : Jefferies initiates coverage with buy rating; price target $97 * Tractor Supply Co TSCO.O : Barclays raises target price to $234 from $1
A
A
A
B
B
C
G
J
I
A
C
F

Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD

BRIEF-Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD April 16 (Reuters) - Amgen Inc AMGN.O : AMGEN INC - PLANNING UNDERWAY FOR PHASE 3 DEVELOPMENT OF TEZEPELUMAB IN COPD Source text for Eikon: ID:nPn24LPZYa Further company coverage: AMGN.O
A

U.S. Advanced Micro Devices, Kroger, Tyson Foods

U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods April 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advanced Micro Devices, Kroger and Tyson Foods, on Tuesday. HIGHLIGHTS * Advanced Micro Devices Inc AMD.O : HSBC raises to buy * CNO Financial Group Inc CNO.N : Piper Sandler raises to overweight from neutral * Endeavor Group Holdings Inc EDR.N : Citigroup cuts to neutral from buy * Kroger Co KR.
A
A
B
B
C
C
G
G
I
N
S
A
A
K
L
A
C
C
C
M

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.